<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The extent to which <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> treatment affects <z:chebi fb="15" ids="39026">LDL</z:chebi> size, <z:chebi fb="15" ids="39026">LDL</z:chebi> subfraction levels and remnant-like particle cholesterol (RLP-C) was determined in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We also compared <z:chebi fb="15" ids="39026">LDL</z:chebi> size and RLP-C in relation to guideline cut-off values for <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo) B </plain></SENT>
<SENT sid="2" pm="."><plain>Changes in <z:chebi fb="15" ids="39026">LDL</z:chebi> size and RLP-C were determined in fasting plasma from type 2 diabetic patients after 30 weeks administration of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (10 mg daily, n=65; 80 mg daily, n=62) or placebo (n=58) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi> subfraction cholesterol was measured in 74 participants </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> lowered <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, apo B and RLP-C (P&lt;0.001 for <z:hpo ids='HP_0000001'>all</z:hpo> at each dose) and <z:chebi fb="15" ids="39026">LDL</z:chebi> mean peak particle diameter remained unchanged </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> treatment decreased cholesterol concentrations in <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="15" ids="39026">LDL</z:chebi> subfractions (P&lt;0.001 for each dose) </plain></SENT>
<SENT sid="6" pm="."><plain>RLP-C at follow-up was lower in those patients achieving the non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> or the apo B guideline targets (P&lt;0.01), but the <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> cut-off value failed to discriminate </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> lowers fasting RLP-C and <z:chebi fb="15" ids="39026">LDL</z:chebi> subfraction cholesterol in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>The proposed guideline cut-off levels for non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and apo B may be superior to the <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> target in discriminating between higher and lower RLP-C levels </plain></SENT>
</text></document>